Filters

Dominik Strzelecki, Michał Podgórski, Oliwia Gawlik-Kotelnicka, Piotr Grzelak, Agnieszka Gmitrowicz, Magdalena Kotlicka-Antczak, Ludomir Stefańczyk, Olga Kałużyńska

Neuroscience letters 2016;606():7-12

Full Text

Abstract

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.

Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange

Biological psychiatry 2004;55(5):452-6

Full Text

Abstract

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.

Yu-Hsin Wu, Guochuan E Tsai, Hsien-Yuan Lane, Shuo-Yen Ting, Ching-Ling Kao, Yue-Cune Chang, Sun-Yuan Liang, Chun-Yuan Lin

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2018;18(5):357-368

Full Text

Abstract

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.

Michael Desch, Christina Schlecker, Kathrin Hohl, Karl-Heinz Liesenfeld, Tom Chan, Fabian Müller, Glen Wunderlich, Sascha Keller, Naoki Ishiguro, Sven Wind

Journal of clinical psychopharmacology 2023;43(2):113-121

Free Full Text

Abstract

Results: 1 – 11 / 11

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Glycine Plasma Membrane Transport Proteins""[mesh_terms]

Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).

Synergistic Control of Transmitter Turnover at Glycinergic Synapses by GlyT1, GlyT2, and ASC-1.

Glycine transporters in schizophrenia. A new hope or informational noise?

The P429L loss of function mutation of the human glycine transporter 2 associated with hyperekplexia.

Spinal astrocytes as therapeutic targets for pathological pain.

Glycine transporter GLYT1 is essential for glycine-mediated protection of human intestinal epithelial cells against oxidative damage.

Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.

Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.

Results for

""Glycine Plasma Membrane Transport Proteins""[mesh_terms]